

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Symbio Holdings Limited</b>
<b>ABN: 37 118 699 853</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Rene Sugo
<b>Date of last notice</b>	15 September 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interest	Indirect interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Avondale Innovations Pty Ltd <The Avondale Family A/C>. Mr Sugo is a Director of Avondale Innovations Pty Ltd	RACS SMSF Pty Ltd <RACS Super Fund A/C>. Mr Sugo is a Director of RACS SMSF Pty Ltd
<b>Date of change</b>	27 November 2023	-
<b>No. of securities held prior to change</b>	1) 6,307,928 2) 325,722 3) 201,756	602,490
<b>Class</b>	1) Fully Paid Ordinary Shares 2) Unquoted Options 3) Performance Rights (FY23 LTIA and FY23 Retention Award)	Fully Paid Ordinary Shares
<b>Number acquired</b>	19,027 Fully Paid Ordinary Shares for the first tranche of the FY23 Retention Award	-

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	Nil	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil	-
<b>No. of securities held after change</b>	1) 6,326,955 Fully Paid Ordinary Shares 2) 325,722 unquoted options (no change) 3) 182,729 Performance Rights (FY23 LTIA and FY23 retention award)	602,490 Fully Paid Ordinary Shares (no change)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Shares under the FY23 Retention Award for the Group CEO and Managing Director as approved by shareholders at the 2022 AGM.	-

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	While the Group CEO and Managing Director is part of Symbio Designated Personnel under the Company's Securities Trading Policy (for whom written clearance would ordinarily be required), written clearance was not required for this conversion of interests as the shares were allocated in accordance with the Company's employee share scheme.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.